EVENTS | VIEW CALENDAR
Telemetry device advances metabolic disease research
SANTA CLARA, Calif.—Crown Bioscience, a wholly owned subsidiary of Crown Bioscience International and a global drug discovery and development services company providing translational platforms to advance oncology, inflammation cardiovascular and metabolic disease research, announced late last year the successful development of an enhanced method for preclinical obesity and type 2 diabetes studies in partnership with Data Sciences International (DSI).
According to Crown, its “clinically relevant models and DSI’s HD-XG implantable glucose device combine to create a superior approach to preclinical metabolic disease research.”
Recently published work in the Journal of Endocrinological Investigation and Scientific Reports demonstrates the advantages of a new method using DSI’s HD-XG implantable glucose device and Crown Bioscience’s models of spontaneous and diet-induced diabetes. The HD-XG device allows for continuous, long-term measurement of blood glucose, temperature and locomotor activity and eliminates stress inducing blood sampling that can inadvertently skew glucose levels and cause blood volume to decline. The published data reportedly support use of this method to thoroughly monitor glucose levels in Crown Bioscience’s clinically relevant models of human metabolic disease.
“We are excited to provide researchers with this powerful new method to advance preclinical obesity and diabetes programs,” said Dr. Jim Wang, Crown Bioscience’s senior vice president for cardiovascular and metabolic diseases research. “By leveraging Crown Bioscience’s models to recapitulate human metabolic disease and DSI’s HD-XG device to reliably investigate changes in blood glucose, researchers can gain unprecedented insight into the pathophysiology of metabolic diseases and the pharmacology of related investigational compounds.”
“We are pleased to collaborate with CrownBio to further promote the adoption of continuous glucose telemetry in research studies,” said Eric Rieux, vice president of global sales and marketing at DSI. “We share a common goal of helping scientists better understand blood glucose levels, and ultimately develop better drugs, devices and therapies for humans.”